Bernard H E Jansen
Overview
Explore the profile of Bernard H E Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
3.
van Altena E, Jansen B, Korbee M, Knol R, Luining W, Nieuwenhuijzen J, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39414419
Background And Objective: Biochemical recurrence (BCR) of prostate cancer (PCa) after curative radiotherapy (RT) is defined according to the Phoenix criteria, which is a prostate-specific antigen (PSA) rise of ≥2.0 ...
4.
Bodar Y, Zwezerijnen B, van der Voorn P, Jansen B, Smit R, Kol S, et al.
Eur J Nucl Med Mol Imaging
. 2021 Nov;
49(5):1731-1742.
PMID: 34725727
Purpose: Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging method for localizing primary prostate cancer (PCa) and for guiding targeted prostate biopsies. [F]DCFPyL positron emission tomography combined with MRI...
5.
Bodar Y, Koene B, Jansen B, Cysouw M, Meijer D, Hendrikse N, et al.
J Nucl Med
. 2021 Jan;
62(9):1264-1269.
PMID: 33509971
In prostate cancer (PCa) patients, the tumor-to-blood ratio (TBR) has been validated as the preferred simplified method for lesional F-DCFPyL (a radiolabeled prostate-specific membrane antigen ligand) uptake quantification on PET....
6.
Meijer D, Luiting H, van Leeuwen P, Remmers S, Jansen B, Bodar Y, et al.
J Urol
. 2021 Jan;
205(4):1108-1109.
PMID: 33493004
No abstract available.
7.
Meijer D, Luiting H, van Leeuwen P, Remmers S, Jansen B, Bodar Y, et al.
J Urol
. 2020 Nov;
205(4):1100-1109.
PMID: 33207138
Purpose: We assessed predictors of short-term oncologic outcomes of patients who underwent salvage radiation therapy for biochemical recurrence after robot-assisted laparoscopic radical prostatectomy without evidence of metastases on prostate specific...
8.
Meijer D, Jansen B, Wondergem M, Bodar Y, Srbljin S, Vellekoop A, et al.
PLoS One
. 2020 Oct;
15(10):e0239414.
PMID: 33021980
Purpose: Radiolabeled Prostate-Specific Membrane Antigen (PSMA) PET/CT is the current standard-of-care for lesion detection in patients with biochemically recurrent (BCR) prostate cancer (PCa). However, rigorous verification of detected lesions is...
9.
Cysouw M, Jansen B, van de Brug T, Oprea-Lager D, Pfaehler E, de Vries B, et al.
Eur J Nucl Med Mol Imaging
. 2020 Aug;
48(2):340-349.
PMID: 32737518
Purpose: Quantitative prostate-specific membrane antigen (PSMA) PET analysis may provide for non-invasive and objective risk stratification of primary prostate cancer (PCa) patients. We determined the ability of machine learning-based analysis...
10.
Jansen B, van Leeuwen P, Wondergem M, van der Sluis T, Nieuwenhuijzen J, Knol R, et al.
Eur Urol Oncol
. 2020 Feb;
4(5):821-825.
PMID: 32088155
Biochemical recurrence of prostate cancer (PCa) after curative radiotherapy is defined as a prostate-specific antigen (PSA) rise of ≥2 ng/ml above the nadir ("Phoenix criteria", 2005). With the introduction of...